Annen K
First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
Hokkaido Igaku Zasshi. 1994 Mar;69(2):301-11.
The Met proto-oncogene product is a tyrosine kinase receptor whose ligand is hepatocyte growth factor (HGF). The Met protein is first synthesized in the hepatocytes as a single chain precursor, or p170MET proreceptor, and is then processed to a mature heterodimer receptor consisting of an extracellular alpha subunit (p50 alpha MET) and a transmembrane beta subunit (p 145 beta MET). The beta subunit has a protein kinase domain which is activated through phosphorylation on tyrosine residue by the binding of HGF to the receptor. In order to elucidate the function of the Met gene product in hepatic disorders, we analyzed the expression and tyrosine phosphorylation of the Met protein on regeneration and carcinogenesis of the liver. For studies on carcinogenesis we used human hepatoma tissues, and for studies on regeneration we used rat hepatectomy. Two antibodies were used for western blotting; a mouse monoclonal anti-phosphotyrosine antibody, which recognizes phosphorylated tyrosine residue in proteins, and a polyclonal rabbit anti-Met antibody, which recognizes the C-terminus of both the Met beta chains and proreceptor. To compare the amount of protein in each experiment, the results of western blotting were evaluated using an image analyzing system. In experiments involving rats with partial hepatectomy, a decreased expression of the proreceptor with a decreased amount of tyrosine phosphorylation was observed within 12 hours of hepatectomy. However, there were no significant changes of the Met beta subunit during the experiment. These data suggest that the Met proreceptor is decreased in the early stages of liver regeneration. In experiments on human samples surgically removed from 18 patients with hepatocellular carcinoma, the met proteins, p 145 beta MET and p 160 MET proreceptor, were expressed both in cancer tissues (12/18, and 10/18, respectively) and in non-cancer tissues (8/18, and 15/18, respectively). From the comparative analyses of the intensity of the signals in cancerous region against those of non-cancerous region in the 18 individual cases, it was demonstrated that expression of p 160 MET proreceptor was increased in non-cancerous region more significantly than in cancerous region (p < 0.05). On the contrary, expression of p145 beta MET was increased in cancerous region more significantly than in non-cancerous region (p < 0.05), except for a few cases of poorly differentiated carcinomas in which p 145 beta MET signal was not detected. These findings suggested that a processing pathway from the proreceptor to the mature Met receptor is amplified in carcinogenesis of the liver.(ABSTRACT TRUNCATED AT 400 WORDS)
Met原癌基因产物是一种酪氨酸激酶受体,其配体是肝细胞生长因子(HGF)。Met蛋白最初在肝细胞中作为单链前体即p170MET前受体合成,然后加工成由细胞外α亚基(p50αMET)和跨膜β亚基(p145βMET)组成的成熟异二聚体受体。β亚基具有蛋白激酶结构域,通过HGF与受体结合使酪氨酸残基磷酸化而被激活。为了阐明Met基因产物在肝脏疾病中的功能,我们分析了肝脏再生和癌变过程中Met蛋白的表达及酪氨酸磷酸化情况。对于癌变研究,我们使用了人类肝癌组织;对于再生研究,我们使用了大鼠肝切除术。用两种抗体进行蛋白质印迹分析;一种是小鼠单克隆抗磷酸酪氨酸抗体,可识别蛋白质中的磷酸化酪氨酸残基,另一种是多克隆兔抗Met抗体,可识别Metβ链和前受体的C末端。为了比较每个实验中的蛋白量,使用图像分析系统评估蛋白质印迹的结果。在部分肝切除大鼠的实验中,肝切除术后12小时内观察到前受体表达降低,酪氨酸磷酸化量减少。然而,实验过程中Metβ亚基无显著变化。这些数据表明肝脏再生早期Met前受体减少。在对18例肝细胞癌患者手术切除的人类样本进行的实验中,met蛋白p145βMET和p160MET前受体在癌组织(分别为12/18和10/18)和非癌组织(分别为8/18和15/18)中均有表达。通过对18个个体病例癌区与非癌区信号强度的比较分析,证明p160MET前受体在非癌区的表达比癌区更显著增加(p<0.05)。相反,p145βMET在癌区的表达比非癌区更显著增加(p<0.05),除了少数低分化癌病例未检测到p145βMET信号。这些发现提示从原受体到成熟Met受体的加工途径在肝脏癌变过程中被放大。(摘要截短至400字)